Apolipoprotein D (ApoD) is a secreted lipocalin associated with neuroprotection and lipid 9 metabolism. Overexpression of ApoD in mouse neural tissue induces the development of a non-10 inflammatory hepatic steatosis in 12-month-old transgenic animals. Previous data indicates that 11 accumulation of arachidonic acid, ApoD's preferential ligand, and overactivation of PPARγ are 12 likely the driving forces in the development of the pathology. However, the lack of inflammation 13 under those conditions is surprising. Hence, we further investigated the apparent repression of 14 inflammation during hepatic steatosis development in aging transgenic animals. The earliest 15 modulation of lipid metabolism and inflammation occurred at 6 months with a transient 16 overexpression of L-PGDS and concomitant overproduction of 15d-PGJ 2 , a PPARγ agonist. 17
INTRODUCTION

31
Apolipoprotein D (ApoD) is a 25 to 30 kDa glycosylated protein member of the lipocalin 32 superfamily [1] [2] [3] [4] . Its known biological functions are associated to its capacity to bind several 33 small hydrophobic molecules [5] . In mice, ApoD expression is limited to the central nervous 34 system (CNS). In humans however, ApoD is expressed in the CNS, adrenal glands, kidneys, 35 pancreas, placenta, spleen, lungs, ovaries and testes [6] . Because ApoD is massively 36 overexpressed (up to 500-fold) during neurodegenerative stress [7, 8] , it has mainly been 37 studied in a neural context. Some of ApoD's functions are mediated by its capacity to bind 38 arachidonic acid (ARA) [9] , a polyunsaturated omega-6 fatty acid with the highest affinity among 39 known ApoD ligands [10] . In recent years, roles for ApoD outside the CNS have begun to 40 emerge. 41
Overexpression of human ApoD (hApoD) in transgenic mice under the neuron-specific THY1 42 promoter triggers a hepatic steatosis without hepatitis at 12 months of age [11] . Transgenic 43 hApoD mouse livers are characterized by an overactivation of the peroxisome proliferator-44 activated receptor gamma (PPARγ) transcription factor, higher expression of the PPARγ target 45 cluster of differentiation 36 (CD36) and higher fatty acid uptake. Lipogenesis, however, is largely 46 unaffected [12] . In general, hepatic lipid accumulation is thought to lead to inflammation which, 47 in turn, exacerbates lipid accumulation (two-hit hypothesis) [13] . This is not the case in the livers 48 of 12 month-old hApoD animals [11] . No data has yet been collected from younger hApoD mice. 49
The absence of hepatic inflammation in the transgenic mouse is particularly intriguing as hApoD 50 livers are rich in ARA [12] , a precursor for series 2 prostaglandins (PGE 2 , PGI 2 , PGD 2 , etc.) and 51 series 4 leukotrienes (LTA 4 , LTB 4 , LTC 4 , etc.) [14] , molecules intimately associated with 52 inflammation. We therefore set out to pinpoint the processes taking place in the livers of aging 53 hApoD mice, specifically lipid accumulation, inflammation modulation and prostaglandin 54 production. Experimental procedures were approved by the Animal Care and Use Committee (CIPA) of the 60 University of Quebec in Montreal (UQAM). Animals were housed at 24 ± 1°C in a 12h light / 12h 61 dark cycle and fed a standard rodent chow (Charles River, #5075) ad libitum with free access to 62 water. Tg(THY1-APOD1)1Era (hApoD) mice, expressing a human APOD cDNA under a 3.5 kb 63 fragment of the human THY1 promoter/enhancer region, were continuously backcrossed with 64 C57BL/6 mice to maintain a heterozygous transgenic population. Experiments were carried out 65 on males aged 3, 6, 9 and 12 months. Mice were first anaesthetised by inhalation of 5% 66 isoflurane and then euthanized by CO 2 inhalation. Blood was promptly collected (~500 µL). 67
Livers were collected, washed in PBS, flash frozen in liquid nitrogen and stored at -80 o C. Mouse 68 genotyping was performed as previously described [11] . DNA concentration was assessed 69 using a NanoDrop 2000 (Thermo Scientific, ND2000). PCR was performed using Taq DNA 70 polymerase (Invitrogen, 18038-042) with 60 ng of DNA and 10mM primers (hApoD forward: 71 ACA AGC ATT TCA TCT TGG GAA GT and reverse: CAT CAG CTC TCA ACT CCT GGT; Actb 72 control forward: GAT GTC ACG CAC GAT TTC CC and reverse: CCC AGC ACA CTG AAC 73 TTA GC). PCR products were separated on 1% agarose gel and visualised after incubation in 74 ethidium bromide 0.5 µg/mL. 75
RNA extraction and quantitative PCR 76
Total RNA was extracted from liver samples using TRIzol Reagent (Life Technologies, 15596-77 018) according to the manufacturer's protocol. Four µg of total RNA was then reverse-78 transcribed to cDNA using SuperScript II reverse transcriptase (Invitrogen, 18064-022) . 79
Quantitative PCR (qPCR) was performed in a LightCycler 480 thermocycler (Roche, 80 05015278001). A preliminary qPCR array was performed using a predesigned prostaglandin 2 81 series biosynthesis and metabolism panel (BioRad, 100-29146) 
Immunoblotting 88
For whole cell extractions, liver samples were homogenized in lysis buffer (50mM Tris-HCl pH 89 7.4, sucrose 250mM, 100mM NaF, 10mM sodium pyrophosphate, 1mM EDTA, 1mM DTT, 1mM 90 sodium vanadate, 1mM PMSF). Lysates were then incubated 30 min at 4 o C, cleared by 91 centrifugation (10,000 g, 15 min). The lipid layer was discarded and protein concentration was 92 assessed by Bradford assay [15] . For nuclear enrichment, liver samples were first homogenised 93 in lysis buffer (10mM HEPES, 1.5mM MgCl 2 , 10mM KCl, 0,5mM DTT and 0.05% NP-40, pH 94 7.9). The nuclear fraction was precipitated by centrifugation (1,500 g, 10 min), then 95 resuspended in a second buffer (5mM HEPES, 1.5mM MgCl 2 , 0.2mM EDTA, 0.5 mM DTT and 96 26% glycerol (v/v), pH 7.9) and homogenised in a Dounce tissue grinder (Wheaton, 357421) . 97
Remaining cell debris were removed by centrifugation (24,000 g, 20 min). Protein concentration 98 was assessed by Bradford assay [15] . Proteins (20 µg) were separated on SDS-PAGE and 99 transferred on PVDF membrane. Blocking was performed using 5% milk, 1h at room 100 temperature. Membranes were then incubated with primary antibodies overnight at 4 o C. 101
Dilutions of the primary antibodies were of 1:50,000 for cyclophilin B (Abcam, ab16045), 1:1000 102
for PPARγ (Abcam, ab45036), SREBP-1 (Santa Cruz, sc13551) FASN (Abcam, ab22759) and 103 NF-κB p50 (Santa Cruz, sc7178). Primary antibodies were detected using goat anti-rabbit HRP 104 conjugated IgG antibodies (Cell Signaling Tech., 7074S) at 1:1000 and visualized by using 105 chemiluminescent HRP substrate (Millipore, WBKLS0500). Amidoblack staining was used as a 106 loading control. Briefly, membranes were stained for 20 min in amidoblack solution (0.1% 107 amidoblack, 40% v/v methanol and 10% v/v acetic acid) and washed 10 min twice in 108 decolouration solution (40% v/v methanol and 10% v/v acetic acid). Bands were quantified by 109 densitometry using Image J software. 110
Enzyme-linked immunosorbent assays 111
Liver extracts were prepared by homogenizing tissues in cold lysis buffer (50mM Tris-HCl pH 112 7.3, 150 mM NaCl, 5 mM EDTA, 0.2% Triton X-100, 2 mM sodium orthovanadate and 10% 113 cOmplete protease inhibitor). Lysates were then incubated 30 min at 4°C and cleared by 114 centrifugation (10000 g, 15 min). The concentration of PGE 2 and 15d-PGJ 2 were then measured 115 using specific ELISA kits (Enzo Life Sciences, PGE 2 : ADI-900-001, 15d-PGJ 2 : ADI-900-023) 116
according to the manufacturer's protocol. For PGD 2 , liver extracts where homogenised in cold 117 PBS. PGD 2 was then measured using the prostaglandin D 2 -MOX Express ELISA Kit (Cayman 118 chemical, 500151). 119
Histology 120
Frozen liver sections were prepared by first freezing samples in NEG-50 (Thermo Scientific, 121 6502) and cutting 4 µm slices with a cryostat (Leica, CM1950). Sections were then fixed in PBS 122 containing 4% paraformaldehyde. To visualise neutral lipids, sections were stained with 0.5% 123
Oil Red O in isopropanol and counterstained with 0.5% hematoxylin. Lipid accumulation was 124 quantified by determining the number of red pixels (Oil Red O-stained lipids) relative to blue 125 pixels (hematoxylin-stained nuclei) using the color threshold function of Image J software.
Paraffin sections were also prepared by fixing liver samples in Bouin's solution overnight at 127 room temperature before paraffin embedding. Microtome 8 µm sections were then stained with 128
Masson's Trichrome. Histology scoring for macrovesicular and microvesicular steatosis, in 129 addition to inflammation foci and fibrosis was performed by an independent hepatologist 130 following a Kleiner scoring system adapted for rodents [16, 17] . 131
Fatty acid profiling 132
Fatty acid composition was measured by a modified gas chromatography-mass spectrometry 133 (GC-MS) method, as previously described [18] . Briefly, total lipids were extracted from plasma 134 with a mixture of methyl tert-butyl ether, methanol and water [19] . For liver, pulverized tissues 135 (25mg) were incubated overnight at 4°C in a solution of chloroform/methanol (2:1) containing 136 0.004% butylated hydroxytoluene, filtered through gauze and dried under nitrogen gas. Plasma 137 and liver fatty acids were analyzed as their fatty acid methyl derivatives (FAME) after direct 138 transesterification with acetyl chloride/methanol [20] . Injections (2 μL for plasma and 1 μL for 139 liver samples) were performed onto an Agilent 7890B gas chromatograph equipped with a 140
Select FAME CP7420 capillary column (100 m; 250 μm inner diameter; 230 μm thickness) 141 coupled with a 5977A Mass Selective Detector operated in positive chemical ionisation mode 142 using ammonia as reagent gas. Fatty acids were identified according to their retention time and 143 m/z, and their concentration was calculated using a mix of internal and external labelled 144 standards added to liver and plasma samples at known concentrations. The concentration of 145 fatty acid is reported relative to total fatty acid content (%). 146
Statistics 147
Results are presented as mean ± standard error mean unless otherwise stated. Statistical 148 analysis was performed with GraphPad 5 software. Statistically significant differences from 149 control values (p-value <0.05 or less) were determined by a one-tailed Student's t-test. A 150
Welch's correction was applied when variances between groups were unequal (as determined 151 by the Fisher's f-test). 
Hepatic lipid accumulation is apparent at 9 months of age
We first examined the livers of wild type (WT) and transgenic hApoD mice at every trimester 157 leading up to 12 months of age. Neutral lipid accumulation ( Fig.1A ) and macrovesicular 158 steatosis ( Fig.1B) were already apparent in transgenic livers at 9 months and increased during 159 the next trimester. Several transgenic hepatic samples reached score 3 macrovesicular 160 steatosis at 12 months, while WT animals of the same age only exhibited early signs of age-161 related steatosis (grade 1; Fig.1B) . No difference in microvesicular steatosis or fibrosis scores 162 were observed between WT and hApoD livers (data not shown). 163
Lipid uptake increases at 6 months 164
Next, we examined the effect of hApoD overexpression on hepatic lipid synthesis by evaluating 165 activation of the transcription factor SREBP-1 and expression of its target FASN. The 166 maturation by cleavage of SREBP-1, the master regulator of hepatic lipogenesis, was not 167 significantly modulated in hApoD mice livers compared to WT controls, except for a slight 168 activation at 12 months ( Fig.2A) . FASN levels were also fairly stable, except for a slight 169 increase at 3 months ( Fig.2B ). We also investigated hepatic lipid uptake via the evaluation of 170
PPARγ and Cd36 levels. PPARγ protein levels were increased in nucleus-enriched fractions of 171 hApoD livers starting at 6 months ( Figs.2C and A1) . This was reflected by an overexpression of 172 its transcription target Cd36 beginning at the same trimester (Fig.2D) . These results further 173 establish lipid uptake via PPARγ activation as the mechanism by which fatty acids accumulate 174 in the livers of hApoD mice [12] . 175
Anti-inflammatory profile at 6 months 176
Despite the pronounced hepatic steatosis established by 12 months of age, hApoD mice do not 177 develop the steatohepatitis that is typically associated with it [21] . To better understand this 178 unexpected phenomenon, we measured the expression of macrophage polarization biomarkers 179 within liver tissue at every trimester. There was a trend toward M1 pro-inflammatory polarization 180 at 3 and 9 months, a trend towards M2 anti-inflammatory polarization at 6 months and a mostly 181 neutral profile at 12 months. These trends were particularly pronounced at 6 and 9 months, as 182 revealed by their respective polarization indexes (Fig.3A) . While transgenic livers appeared to 183 experience episodes of pro-inflammatory polarization, these did not result in increased 184 macrophage recruitment. In fact, the severity of inflammatory foci was never elevated relative to 185 WT controls (Fig.3B) . Interestingly, no inflammatory foci could be observed in 6-month-old M2-186 polarized hApoD livers. This correlates with a strong reduction of the nuclear recruitment of NF-187 κB (p50) at 6 months and a moderate reduction at 12 months (Fig.3C ).
Overproduction of prostaglandin D 2 and 15d-PGJ 2 189
We next examined whether ARA accumulation in aging hApoD transgenic livers [12] translated 190 into an overproduction of prostaglandins. A preliminary qPCR screen (Fig.A1) , guided our 191 investigation towards the production of two specific prostaglandins: PGE 2 and PGD 2 . We also 192 chose to investigate 15d-PGJ 2 , a non enzymatic derivative of PGD 2 , because of its potent anti-193 inflammatory and pro-lipogenic properties [22] [23] [24] . We observed an increase in the hepatic 194 expression of COX-2 (Ptgs2 gene) and L-PGDS (Ptgds gene) at 6 months (Fig.4A) , two 195 enzymes participating in the conversion of ARA into PGD 2 . Accordingly, we observed a 196 significant increase of the anti-inflammatory prostaglandin 15d-PGJ 2 at 6 months (Fig.4B) . We 197 also observed increased PGD 2 levels at 12 months. The pro-inflammatory prostaglandin PGE 2 198 remained unmodulated at all trimesters, a result consistent with our previous published data on 199 12-month-old hApoD livers [12] . 200
Omega fatty acid accumulation during aging 201
To better understand the steatosis process in hApoD livers, we measured a large panel of fatty 202 acids in aging hApoD and WT livers, including several saturated, mono-unsaturated and omega 203
(ω)-3/6/9 fatty acids ( Figs.A2 and A3) . In WT livers, the proportion of [saturated + mono-204 unsaturated] fatty acids among the total pool of fatty acids increased progressively with age 205 (Fig.5A ) while the proportion of [ω-3 + ω-6] fatty acids diminished (Fig.5B ). This was not 206 observed in transgenic fatty livers, as these fatty acid proportions were similar at all ages. In 207 addition, every ω-3 and ω-6 fatty acid quantified in our experiment was elevated in 12-month-208 old hApoD fatty livers compared to WT controls (Fig.5C ). Interestingly, in terms of inflammation 209 potential, the ω-3/ω-6 fatty acid ratio in hApoD livers was lower at 3 months and higher at 12 210 months ( Fig.5D ). As ApoD is a secreted protein [1, 4, 25, 26] , we hypothesized that its 211 overexpression might modify circulating lipid levels. Indeed, compared to WT mice, the 212 plasmatic ω-6 fatty acids ARA and dihomo-γ-linoleic acid (DGLA) were lowered while the ω-3 213 docosapentaenoic acid (DPA) was slightly increased in 12-month-old hApoD mice (Fig.5E) . 214 215 216
DISCUSSION
217
Our previous study has implicated an increase in lipid uptake associated with PPARγ activation 218 in the development of hepatic steatosis in hApoD mice [12] . Fatty acid accumulation is typically 219 associated with hepatic inflammation (steatohepatitis) [27] . The goal of this new study was to 220 provide a better understanding of the intriguing absence of inflammation in the hApoD fatty liver. 221 A model explaining our findings is presented in Figure 6 . 222
The earliest event we uncovered was the production of 15d-PGJ 2 in 6-month-old hApoD livers 223 (Fig.4B) , a full trimester before hepatic lipid accumulation was detectable by microscopy 224 analysis. This prostaglandin being a strong PPARγ agonist [28], 15d-PGJ 2 could be directly 225 responsible for PPARγ activation in hApoD livers. Despite the fact that 15d-PGJ 2 was only 226 transiently overproduced, PPARγ remained activated in the following trimesters. The Cd36 gene 227 is transcriptionally activated by PPARγ [29] . Consequently, increased expression of CD36 which 228 mediates the cellular uptake of long chain fatty acids (LCFA) and poly-unsaturated fatty acids 229 (PUFA) [30, 31] leads to increased LCFA and PUFA concentration that can in turn, activate 230
PPARγ [32] . Therefore, increased CD36 expression could result in a positive feedback loop 231 maintaining PPARγ activation after 6 months. 232
The IKK/NF-κB pathway plays an important role in liver inflammation [33] . Prostaglandin 15d-233 PGJ 2 can inhibit NF-κB signaling through PPARγ-dependent and -independent mechanisms. 234
Agonist-bound PPARγ reduces NF-κB transcriptional activity in a dose-dependent manner [34] . 235
Moreover, 15d-PGJ 2 can disrupt NF-κB signaling through covalent modification of a cysteine 236 residue (Michael addition reaction) in IKK and in the DNA binding domain of NF-κB itself [35, 237 36] . The overproduction of 15d-PGJ 2 was indeed concomitant to a strong inhibition of NF-κB 238 (p50) nuclear recruitment at 6 months (Fig.3C) . By inhibiting NF-kB signaling, 15d-PGJ 2 239 production could contribute to the strong anti-inflammatory profile observed in hApoD livers at 6 240 months, where the severity of inflammation foci tended to be even lower than in WT livers 241 ( Fig.3B ). In fact, injection of 15d-PGJ 2 was previously shown to inhibit hepatic inflammation in 242 vivo [37, 38] . PGD 2 is an unstable compound and the molecular precursor of 15d-PGJ 2 and 243 other J 2 prostaglandins through non-enzymatic reactions. We found that PGD 2 levels seemed to 244 be higher at 6 months and were significantly higher at 12 months in hApoD mice livers. Like 245 15d-PGJ 2 , PGD 2 plays anti-inflammatory functions in the liver [39] . Thus, PGD 2 could help 246 promote an anti-inflammatory environment in 12-month-old hApoD mice livers. 247
Another mitigating factor towards the advent of steatohepatitis is the fact that a great proportion 248 of fatty acids identified in the hApoD fatty liver were ω-6 and ω-3 PUFA. Lipotoxicity is typically 249 associated with accumulation of saturated fatty acids such as palmitate [40] and mono-250 unsaturated fatty acids like oleate [41] . Relative to WT controls, transgenic fatty livers 251 accumulate a smaller proportion of saturated and mono-unsaturated LCFA in favour of ω-6 and 252 ω-3 fatty acids (Fig.5A&B ). In addition, as ω-3 fatty acids possess anti-inflammatory properties 253 [42, 43] . The higher ω-3/ω-6 ratio presumably contributes to inflammation suppression in hApoD 254 livers (Fig.5C) . 255
The circulating lipid transporter ApoD could directly contribute to fatty acid accumulation in 256 transgenic livers. ApoD has been shown to be internalized in several cell types [44] [45] [46] , a 257 process that could participate in intracellular lipid accumulation. ARA, the ApoD ligand with the 258 highest known affinity [1, 47] , is accordingly depleted in plasma and accumulates in hApoD liver 259 tissue. However, transgenic livers accumulated not only ARA but also all the other ω-3 and ω-6 260 fatty acids measured in our study (Fig.5D ). This suggests that ApoD could bind many different 261 ω fatty acids and transport them to the liver. In accordance with this concept, DGLA (C20:3n6), 262 which is structurally similar to ARA (C20:4n6), was also depleted from hApoD plasma (Fig.5E) . 263
The production of 15d-PGJ 2 in 6-month-old hApoD livers was presumably due to the 264 concomitant expression of COX-2 and L-PGDS (Fig.4A ). However, the events responsible for 265 the increase in COX-2 and L-PGDS expression are still not known. One possibility is that a sub-266 population of liver tissue cells are first affected by circulating ApoD in transgenic mice. 267
Endothelial cells would be the first liver cells to come in contact with circulating lipid-charged 268
ApoD. Hepatic endothelial cells express L-PGDS (Ptgds gene) [48] [49] [50] [51] [52] . Therefore, 15d-PGJ 2 269 overproduction could be the result of ARA transformation within endothelial cells. Hepatocytes 270 also express L-PGDS [53, 54] , but despite their prevalence in liver tissue (roughly 92.5% of liver 271 mass), they only produce a small proportion of total hepatic eicosanoids (12%) compared to 272 endothelial and Kupffer cells (23% and 65%, respectively) [55] . While Kupffer cells are known to 273 produce 15d-PGJ 2 , their ability to do so is not dependent upon the Ptgds gene but upon Hpgds 274
[56, 57] which was not modulated in hApoD livers. Together, these considerations highlight the 275 possibility that hepatic endothelial cells are implicated in the early inflammatory and metabolic 276 processes taking place in the hApoD mouse liver (Fig.7) . 277
The expression of COX-2 and L-PGDS is dependent on several transcription factors, one of 278 which is NF-κB. However, the mRNA overexpression observed in hApoD livers at 6 months 279 ( Fig.4A ) cannot be dependent on NF-kB since it is underactivated (Fig.3C ). Other transcription 280 The overproduction of 15d-PGJ 2 at 6 months could activate the PPARγ transcription factor and 517 trigger CD36 expression. CD36 mediates hepatic lipid uptake, which could create a feedback 518 loop maintaining PPARγ activation after 6 months. Inflammation could be suppressed by 15d-519 PGJ 2 -mediated inhibition of the IKK/NF-kB pathway. The overproduction of PGD 2 and 520 preferential accumulation of ω-3 fatty acids by 12 months of age could also contribute to 521 inflammation control. Hepatic macrophage polarization is represented along the timeline arrow: 522 green indicates anti-inflammation polarization and red indicates pro-inflammation polarization. 523
Blue lines indicate anti-inflammatory mechanism at relevant trimesters. 524 Considering ApoD's capacity to bind ARA, it is highly plausible that its overexpression increases 527 ARA transport to the liver. ARA import within hepatic endothelial cells could result in 15d-PGJ 2 528 production and diffusion, activating lipid uptake in hepatocytes as well as promoting M2 anti-529 inflammatory polarization in Kupffer cells and/or invading monocytes/macrophages. 530 531 532 533
